G

Genfit SA
PAR:GNFT

Watchlist Manager
Genfit SA
PAR:GNFT
Watchlist
Price: 4.08 EUR 1.49% Market Closed
Market Cap: 203.4m EUR
Have any thoughts about
Genfit SA?
Write Note

Intrinsic Value

GNFT's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one GNFT stock under the Base Case scenario is 4.97 EUR. Compared to the current market price of 4.08 EUR, Genfit SA is Undervalued by 18%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GNFT Intrinsic Value
4.97 EUR
Undervaluation 18%
Intrinsic Value
Price
G
Worst Case
Base Case
Best Case

Valuation Backtest
Genfit SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for GNFT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about GNFT?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Genfit SA

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Genfit SA

Provide an overview of the primary business activities
of Genfit SA.

What unique competitive advantages
does Genfit SA hold over its rivals?

What risks and challenges
does Genfit SA face in the near future?

Has there been any significant insider trading activity
in Genfit SA recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Genfit SA.

Provide P/S
for Genfit SA.

Provide P/E
for Genfit SA.

Provide P/OCF
for Genfit SA.

Provide P/FCFE
for Genfit SA.

Provide P/B
for Genfit SA.

Provide EV/S
for Genfit SA.

Provide EV/GP
for Genfit SA.

Provide EV/EBITDA
for Genfit SA.

Provide EV/EBIT
for Genfit SA.

Provide EV/OCF
for Genfit SA.

Provide EV/FCFF
for Genfit SA.

Provide EV/IC
for Genfit SA.

Show me price targets
for Genfit SA made by professional analysts.

What are the Revenue projections
for Genfit SA?

How accurate were the past Revenue estimates
for Genfit SA?

What are the Net Income projections
for Genfit SA?

How accurate were the past Net Income estimates
for Genfit SA?

What are the EPS projections
for Genfit SA?

How accurate were the past EPS estimates
for Genfit SA?

What are the EBIT projections
for Genfit SA?

How accurate were the past EBIT estimates
for Genfit SA?

Compare the revenue forecasts
for Genfit SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Genfit SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Genfit SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Genfit SA compared to its peers.

Compare the P/E ratios
of Genfit SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Genfit SA with its peers.

Analyze the financial leverage
of Genfit SA compared to its main competitors.

Show all profitability ratios
for Genfit SA.

Provide ROE
for Genfit SA.

Provide ROA
for Genfit SA.

Provide ROIC
for Genfit SA.

Provide ROCE
for Genfit SA.

Provide Gross Margin
for Genfit SA.

Provide Operating Margin
for Genfit SA.

Provide Net Margin
for Genfit SA.

Provide FCF Margin
for Genfit SA.

Show all solvency ratios
for Genfit SA.

Provide D/E Ratio
for Genfit SA.

Provide D/A Ratio
for Genfit SA.

Provide Interest Coverage Ratio
for Genfit SA.

Provide Altman Z-Score Ratio
for Genfit SA.

Provide Quick Ratio
for Genfit SA.

Provide Current Ratio
for Genfit SA.

Provide Cash Ratio
for Genfit SA.

What is the historical Revenue growth
over the last 5 years for Genfit SA?

What is the historical Net Income growth
over the last 5 years for Genfit SA?

What is the current Free Cash Flow
of Genfit SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Genfit SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Genfit SA

Current Assets 136.4m
Cash & Short-Term Investments 61.6m
Receivables 71m
Other Current Assets 3.7m
Non-Current Assets 58.4m
Long-Term Investments 3.4m
PP&E 8.1m
Intangibles 46.9m
Current Liabilities 36.4m
Accounts Payable 22.2m
Accrued Liabilities 11k
Other Current Liabilities 14.3m
Non-Current Liabilities 61m
Long-Term Debt 59.8m
Other Non-Current Liabilities 1.2m
Efficiency

Earnings Waterfall
Genfit SA

Revenue
84m EUR
Cost of Revenue
-2.2m EUR
Gross Profit
81.8m EUR
Operating Expenses
-58m EUR
Operating Income
23.9m EUR
Other Expenses
-1.6m EUR
Net Income
22.3m EUR

Free Cash Flow Analysis
Genfit SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

GNFT Profitability Score
Profitability Due Diligence

Genfit SA's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Positive 3-Year Average ROE
Exceptional 1-Year Revenue Growth
51/100
Profitability
Score

Genfit SA's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

GNFT Solvency Score
Solvency Due Diligence

Genfit SA's solvency score is 52/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Negative Net Debt
52/100
Solvency
Score

Genfit SA's solvency score is 52/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GNFT Price Targets Summary
Genfit SA

Wall Street analysts forecast GNFT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GNFT is 9.55 EUR with a low forecast of 7.07 EUR and a high forecast of 12.08 EUR.

Lowest
Price Target
7.07 EUR
73% Upside
Average
Price Target
9.55 EUR
134% Upside
Highest
Price Target
12.08 EUR
196% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for GNFT?

Click here to dive deeper.

Dividends

Genfit SA
does not pay dividends
Shareholder Yield

Current shareholder yield for GNFT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

GNFT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Genfit SA

Country

France

Industry

Biotechnology

Market Cap

203.3m EUR

Dividend Yield

0%

Description

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France. The company went IPO on 2006-12-19. The firm is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The firm targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.

Contact

HAUTS-DE-FRANCE
LOOS
Parc Eurasante 885 avenue Eugene Avinee
+33320164000.0
www.genfit.fr

IPO

2006-12-19

Employees

122

Officers

Co-Founder & Chairman of the Board
Mr. Jean-Francois Mouney
Chief Executive Officer
Mr. M. Pascal Prigent
Co-Founder & Chairman of the Scientific Advisory Board
Prof. Bart Staels
Chief Financial Officer
Mr. Thomas Baetz
Chief Operating Officer
Mr. Pascal Caisey
Chief Technology Officer
Dr. Meriam Kabbaj Ph.D.
Show More
Chief Scientific Officer
Dr. Dean W. Hum Ph.D.
Chief Corporate Affairs Officer, Head of Investor Relations & Head of ESG
Mr. Jean-Christophe Marcoux
Corporate Secretary & Director of Legal Affairs
Mr. Laurent Lannoo
Chief Compliance Officer & Executive VP of International Legal Affairs
Ms. Stefanie Magner J.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one GNFT stock?

The intrinsic value of one GNFT stock under the Base Case scenario is 4.97 EUR.

Is GNFT stock undervalued or overvalued?

Compared to the current market price of 4.08 EUR, Genfit SA is Undervalued by 18%.

Back to Top